Venture Kick

Unomr develops novel nano-​micro technology based sensing approaches for diagnostics and drug discovery.

REMUUN is a biotechnology company focused on revolutionizing the development of therapeutic antibodies. It has created the MEGA platform, which mimics natural antibody gene modification and employs AID-based gene editing. This technology enables clients to accelerate, reduce costs, and enhance precision in the creation of monoclonal antibody therapies.

CellX Biosolutions specializes in sustainable chemical waste management. It offers services such as custom bacterial community biodiscovery and optimization, biodegradability studies, and deployment using microfluidic devices. The company helps industries treat pollutants like PFAS, pharmaceuticals, and microplastics, and enables chemical and pharmaceutical producers to manage their waste cost-effectively and sustainably.

Azure Cell Therapies is a biotech company developing next-gen CGTs for neurodegenerative diseases

BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments

Shape Biopharmaceuticals is a biotechnology company that specializes in the development of immunotherapeutic drugs aimed at treating chronic diseases with limited treatment options. The company focuses on advanced protein design and formulation technologies to create a new generation of immunotherapies. By addressing unmet medical needs, Shape Biopharmaceuticals seeks to improve patient outcomes for individuals with genetically driven conditions who lack effective therapeutic alternatives. Through its innovative healthcare solutions, the company aims to provide hope and enhance treatment possibilities for patients facing significant health challenges.

Nerai Bio is a biotechnology company that specializes in advancing genetic therapies. It operates an AI-assisted CRISPR protein engineering platform, enabling clients to enhance the development of next-generation therapeutic systems.

CellX Biosolutions specializes in sustainable chemical waste management. It offers services such as custom bacterial community biodiscovery and optimization, biodegradability studies, and deployment using microfluidic devices. The company helps industries treat pollutants like PFAS, pharmaceuticals, and microplastics, and enables chemical and pharmaceutical producers to manage their waste cost-effectively and sustainably.

Translation-X is a biotechnology company specializing in the development of innovative therapeutics for Autism Spectrum Disorders (ASD). It employs a precision medicine strategy to target core symptoms of ASD, such as social interaction difficulties, aiming to provide effective treatment options for affected individuals.

ValTech Lifesciences is a medtech startup promoting cardiovascular health through its proprietary heart valve characteristics that improve the performance of mechanical and biological prostheses.

Abrinca Genomics is a biotechnology company specializing in the development of a web-based platform for managing and analyzing microbial genomics data. The platform is designed to be self-hosted, scalable, and dataset-independent, allowing researchers and bioinformaticians to securely organize, explore, and analyze vast volumes of microbial genome data. It supports multiple annotation formats, offers flexible access controls, and integrates seamlessly into existing workflows.

Amporin Pharmaceuticals seeks to create a new class of small-molecule medications that block and eradicate harmful soluble oligomers and holes found within cell membranes.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

TrueYouOmics specializes in comprehensive blood testing services, leveraging multi-omics and artificial intelligence to identify disease risks and facilitate preventive health planning. The company's innovative approach involves analyzing an individual's DNA, RNA, and protein data, then integrating these insights with medical knowledge graphs to estimate personalized disease risks. This holistic health assessment empowers individuals to proactively manage their well-being by taking preventive measures.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

Procavea Biotech specializes in developing a drug delivery platform utilizing non-viral protein cages. This innovative technology is tailored specifically for veterinary professionals, aiming to streamline and improve the efficiency of veterinary practice management. By providing a comprehensive solution, Procavea Biotech enhances the overall effectiveness of veterinary services, allowing practitioners to integrate processes seamlessly and elevate the quality of care offered to their clients.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

Transpire Bio is a biotechnology platform focused on the development of inhaled therapeutics aimed at improving healthcare outcomes globally. The company specializes in the commercialization of lower-cost generic alternatives for injectable drugs, utilizing innovative delivery methods to enhance patient experience by providing painless administration. Transpire Bio's product portfolio includes medicines and inhalation therapies targeting both lung diseases and systemic conditions, reflecting its commitment to addressing a wide range of health challenges through advanced biopharmaceutical solutions.

PlasNifix is a technology company that has developed a novel process for nitrogen fixation, using plasma assistance to enable the production of ammonia and other nitrogen-containing compounds at lower temperatures and with significantly less energy. This innovative method relies on proprietary catalysts and plasma generators, facilitating a more efficient and sustainable production process that can help agricultural and fertilizer industries reduce their dependence on fossil fuels.

Gaia Technologies specializes in transforming agricultural byproducts into valuable ingredients through an innovative and scalable extraction process. The company focuses primarily on olive waste, utilizing its technology to convert these sidestreams into bio-compounds such as antioxidants, biochar, activated carbon, and biogas. By addressing the growing demand for natural alternatives to synthetic compounds in the cosmetics, food, and feed industries, Gaia Technologies not only creates new value streams for primary sector firms but also contributes to reducing their environmental impact. The company's approach is designed to support a circular economy within the food production sector by enabling the substitution of synthetic and fossil-based ingredients with those derived from agricultural waste.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

ASTRA Therapeutics is a medication development company focused on creating innovative therapies for parasitic diseases. Utilizing advanced science and technology, the company develops precision-engineered drugs to combat a wide range of parasitic disorders, including malaria, cryptosporidiosis, and toxoplasmosis. Its mission is to address the global health burden posed by these conditions by bringing effective treatment candidates to market.

metaLead Therapeutics is a biopharmaceutical company focused on developing innovative peptide medications to address metal-related diseases, particularly lead poisoning. The company’s research centers on creating a next-generation treatment that specifically targets and binds lead ions while safeguarding essential metal ions in the body. This targeted approach results in a highly stable medication that can be administered both orally and intravenously. By providing an effective detoxification solution, metaLead Therapeutics aims to improve the health outcomes of individuals affected by lead poisoning on a global scale.

Tandem Therapeutics is a biopharmaceutical company dedicated to pioneering treatments for fibrotic diseases. It focuses on the extracellular matrix, a complex network of proteins that surrounds cells, and develops peptide therapeutics, known as Matrix Targeting Peptides (MTPs), to target and treat the extracellular matrix barrier. This innovative approach aims to provide more precise and effective treatments for patients suffering from fibrotic conditions, including cancers and organ fibrosis.

Adularia is a microbial-based therapy for Colorectal cancer.

Aukera Therapeutics is a biotechnology company focused on creating innovative therapeutics for patients afflicted by diseases related to the mTOR protein, including cancer and neurodegenerative disorders. Originating as a spin-off from the Biozentrum of the University of Basel, the company has developed a pharmaceutical drug discovery engine aimed at producing selective inhibitors of the mTOR complex. This technology enables the development of drugs that specifically target various branches of the mTOR signaling pathway, which plays a crucial role in regulating cell growth. By providing targeted treatments, Aukera Therapeutics seeks to improve patient outcomes in the management of mTOR-related diseases.

Biosimo Chemicals is a chemical engineering start-up focused on the development and operation of processes to produce bio-based platform chemicals. The company aims to create sustainable chemical solutions through innovative catalytic reactions and purification processes. Its flagship technology offers a novel method for producing acetic acid, replacing traditional methods that rely on coal and gas with a process that utilizes ethanol derived from biomass and waste. This advancement provides the chemical, pharmaceutical, and materials industries with a direct alternative to fossil-based resources, aligning with global sustainability goals.

FimmCyte is a biotechnology company focused on developing innovative disease-modifying treatments for fibro-inflammatory diseases, with an initial emphasis on Endometriosis. The company aims to accelerate the path toward a cure for endometriosis by addressing significant healthcare requirements and advancing novel ideas in women's health. FimmCyte's mission is to empower women to take control of their health and meet their unmet medical needs through cutting-edge treatments.

SURI BioTech is a biotechnology company focused on the development of health-promoting bacterial strains designed to alleviate bloating and intestinal discomfort. The company's proprietary strains work by reducing the production of hydrogen gas by intestinal microorganisms, providing potential therapeutic benefits for various functional gastrointestinal disorders, including infant colic and lactose intolerance. SURI BioTech employs a scientific approach to create probiotics that specifically target gastrointestinal health, thereby offering solutions for individuals suffering from digestive issues. Their innovative platform contributes to ongoing advancements in the treatment of gastrointestinal illnesses.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.

Reactive Illumination proposes an innovative green way to convert any organic waste (biowaste, tyres etc.) to mainly solid carbon and energy-efficient gases like H2, CH4, etc. within seconds without any chemicals that can be collected and used.

Avelo is a manufacturer of breath aerosol diagnostic equipment focused on providing rapid testing solutions for infectious diseases. The company has developed a non-invasive sample-to-answer breath test that reliably detects multiple lower respiratory tract infections within minutes. This process involves three simple steps, allowing healthcare providers to make timely and informed decisions regarding antibiotic or antiviral treatments. Avelo's innovative approach aims to enhance the speed and accuracy of diagnoses in primary care settings, ultimately contributing to improved patient outcomes and the potential to save lives through early intervention.

NexMR is a Swiss company specializing in nuclear magnetic resonance (NMR) technology to enhance drug discovery processes. It provides key-in-hand solutions that optimize resource use and increase throughput within drug discovery pipelines. The company's platform accelerates screening processes by integrating machine learning for data analysis, enabling efficient exploration of uncharted target spaces. NexMR's proprietary NMR techniques allow for the rapid screening of extensive libraries of molecules, streamlining the evaluation of new compounds and improving the turnaround time for experimental results. Additionally, its technology serves quality control purposes, assisting researchers in determining the content, purity, and molecular structure of chemical samples, which aids healthcare professionals in assessing the viability of potential new drugs.

Biosimo Chemicals is a chemical engineering start-up focused on the development and operation of processes to produce bio-based platform chemicals. The company aims to create sustainable chemical solutions through innovative catalytic reactions and purification processes. Its flagship technology offers a novel method for producing acetic acid, replacing traditional methods that rely on coal and gas with a process that utilizes ethanol derived from biomass and waste. This advancement provides the chemical, pharmaceutical, and materials industries with a direct alternative to fossil-based resources, aligning with global sustainability goals.

inSEIT provides an integral service for enzyme immobilization, from the matching between enzymes and supports to the application and process scale-up.

Adularia is a microbial-based therapy for Colorectal cancer.

NexMR is a Swiss company specializing in nuclear magnetic resonance (NMR) technology to enhance drug discovery processes. It provides key-in-hand solutions that optimize resource use and increase throughput within drug discovery pipelines. The company's platform accelerates screening processes by integrating machine learning for data analysis, enabling efficient exploration of uncharted target spaces. NexMR's proprietary NMR techniques allow for the rapid screening of extensive libraries of molecules, streamlining the evaluation of new compounds and improving the turnaround time for experimental results. Additionally, its technology serves quality control purposes, assisting researchers in determining the content, purity, and molecular structure of chemical samples, which aids healthcare professionals in assessing the viability of potential new drugs.

Adaptyv Bio is a biotechnology company focused on developing a protein engineering platform that leverages cell-free synthetic biology and high-throughput nanofluidics. The company's innovative technology aims to identify new antibodies for the treatment of various diseases by bridging the gap between computational predictions and experimental validation. Through its advanced methodologies, Adaptyv Bio seeks to enhance the efficacy of therapeutic interventions, ultimately improving patient outcomes.

Galventa is a company dedicated to improving sleep and wakefulness through innovative technological solutions. They specialize in developing clinically tested galenic platform technologies designed to enhance sleep quality and mitigate symptoms of sleep inertia. Their primary product is a food supplement based on micro-pellets, engineered to create time-controlled release systems. This supplement aims to regulate the sleep-wake cycle and synchronize the circadian clock, helping individuals with sleep inertia align their sleep patterns with their daily routines.

Oncobit is a company dedicated to enhancing personalized cancer care through the development of precise and highly sensitive diagnostic and monitoring tests. By leveraging a unique combination of technical expertise, proprietary software, and strong clinical collaborations, Oncobit aims to improve patient outcomes in cancer treatment. Initially focusing on melanoma, the company's solutions are designed to be adaptable for other cancer types in the future. Oncobit's innovations are intended to ensure that personalized therapies and diagnostics align with the evolving needs of clinics, providing essential information that enables healthcare providers to improve patient care and outcomes through more comprehensive and sensitive testing methods.

Bottneuro is a company focused on developing innovative therapies for early to moderate-stage Alzheimer's Disease patients. Utilizing its proprietary NENI technology platform, Bottneuro creates non-invasive stimulation protocols that target neurons and glial cells in the brain. In addition to its work in Alzheimer's treatment, the company has developed a brain therapy system designed to alleviate chronic neuropathic pain. This system employs plant-based components and features a 3D printed cap that allows for continuous monitoring and targeted delivery of active substances within the body. By addressing the specific needs of patients with early to mild Alzheimer's disease, Bottneuro aims to enhance their quality of life through improved treatment options and medical care.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Nemosia is a company focused on the development of positron emission tomography (PET) tracers aimed at diagnosing neurological disorders. Utilizing advanced technology, Nemosia creates tracers that facilitate the early detection of neurodegenerative diseases by visualizing N-methyl-D-aspartate (NMDA) receptors in the brain. This innovative approach allows for timely intervention, enabling patients to take proactive measures against neurological conditions. Through its specialized PET imaging capabilities, Nemosia contributes to improved diagnostic accuracy and better patient outcomes in the field of neurology.

ArcoScreen is a Swiss medtech company focused on advancing drug discovery through its innovative microfluidic platform. This platform specializes in drug screening that targets cell membrane receptors, offering a faster and more efficient method for conducting chip-based GPCR assays. By enabling the identification of a drug's mode of action directly on patient cells, ArcoScreen's technology allows for the simultaneous testing of proteins that make up the drugs, assessing their efficacy in a single test. This approach aims to facilitate the treatment of complex diseases such as cancer, Alzheimer's, and diabetes, ultimately enhancing the drug development process for researchers.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Galventa is a company dedicated to improving sleep and wakefulness through innovative technological solutions. They specialize in developing clinically tested galenic platform technologies designed to enhance sleep quality and mitigate symptoms of sleep inertia. Their primary product is a food supplement based on micro-pellets, engineered to create time-controlled release systems. This supplement aims to regulate the sleep-wake cycle and synchronize the circadian clock, helping individuals with sleep inertia align their sleep patterns with their daily routines.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

Neurosoft Bioelectronics is a Swiss company specializing in the development of soft implantable electrodes designed for interfacing with the nervous system. The company focuses on creating advanced neural implants that can record and stimulate the brain, spinal cord, and peripheral nerves, addressing the limitations of traditional stiff devices that hinder patient outcomes. Its flagship product, the SOFT ECoG, is a subdural electrode that facilitates effective brain monitoring and stimulation while minimizing electrical resistance and MRI artifacts. This innovative technology aims to achieve long-term bio-integration with neural tissues, adapting to both static and dynamic mechanical properties, which enhances therapeutic capabilities for patients suffering from neurological disorders. Ultimately, Neurosoft Bioelectronics strives to improve clinical outcomes and expand the potential applications of neural interfaces in healthcare.

Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

Bionomous is a biotechnology company that specializes in the development of devices designed to automatically observe, analyze, and sort small biological entities. By integrating innovative micro-engineering design with advanced machine learning techniques, Bionomous's technology facilitates the automatic inspection and sorting of miniature biological entities. This capability is particularly beneficial for studies in genetics, development, behavioral biology, and toxicology, allowing biotech companies to automate critical processes such as visual inspection, sorting, and dispensing. Through its cutting-edge solutions, Bionomous aims to enhance efficiency and accuracy in biological research and applications.

peakPCR develops Polymerase Chain Reaction (PCR) devices for research and private laboratories. peakPCR is a low-cost, small size device capable of performing real-time polymerase chain reaction (qPCR). PCR is a method widely used in molecular biology to duplicate DNA segments, with applications such as genotyping, mutation detection, forensics, and paternity testing. The Polymerase Chain Reaction (PCR) is a widely used molecular technique to make millions of copies of a DNA sample, with applications in a variety of fields such as medical diagnostics, biotechnology, and forensic sciences. We have analyzed the heat transfer limitations of conventional PCR machines. This has led to the design of a completely new sample holder with extremely high heating and cooling rates and a much lower sample volume, in order to cut analysis time from currently 1-2 h down to 10 minutes, and reagent consumption by 90%. Next to a first stand-alone desktop instrument, we have also developed a portable version that is battery-powered and that operates in conjunction with a smartphone. We aim to deploy these PCR devices to research and private laboratories at affordable prices.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

Bloom Biorenewables Ltd is a Swiss company established in 2019, specializing in the development of innovative technologies that convert wood and agricultural waste into renewable materials as substitutes for petroleum-based products. The company focuses on producing bio-based materials for various sectors, including fragrances, plastics, and textiles, thereby offering sustainable alternatives to fossil fuels. By introducing a novel approach to the production of biorenewable products and fuels, Bloom Biorenewables aims to make a significant impact in promoting the use of sustainable resources and addressing climate change challenges.

LifeMatrix is a biotechnology company focused on the development of biomimetic implants and bio-engineering technologies aimed at treating cardiovascular diseases and facilitating the growth of human replacement tissues. The company specializes in human cell-derived, off-the-shelf tissue-engineered implants that integrate with the patient's body post-implantation, allowing them to grow and regenerate. This innovative approach addresses the limitations of traditional implants, promoting faster recovery and improved outcomes for patients. LifeMatrix's technology is supported by over 20 years of research, resulting in more than 100 peer-reviewed publications and extensive preclinical studies demonstrating safety and efficacy, paving the way for clinical applications. The company's advancements are bolstered by various national and international research grants, reflecting its commitment to transforming the field of regenerative medicine.

Bionomous is a biotechnology company that specializes in the development of devices designed to automatically observe, analyze, and sort small biological entities. By integrating innovative micro-engineering design with advanced machine learning techniques, Bionomous's technology facilitates the automatic inspection and sorting of miniature biological entities. This capability is particularly beneficial for studies in genetics, development, behavioral biology, and toxicology, allowing biotech companies to automate critical processes such as visual inspection, sorting, and dispensing. Through its cutting-edge solutions, Bionomous aims to enhance efficiency and accuracy in biological research and applications.

Nutrix is a Swiss health-tech company based in Basel, founded in 2019, that specializes in developing innovative healthcare solutions. The company's flagship product is a nanosensor that is placed on the tooth to measure glucose levels in saliva, which communicates data to an external application. This technology not only tracks food intake but also offers dietary recommendations to help prevent diabetes. Nutrix aims to enhance health monitoring through precision medicine by combining advanced AI with wearables and digital coaching. In 2025, the company plans to launch CortiSense, a non-invasive cortisol monitoring sensor, further expanding its range of health monitoring solutions. By providing cost-effective and user-friendly tools, Nutrix seeks to empower individuals to manage their health proactively, reducing the need for frequent medical consultations.

Flowbone is a Swiss company based in Lausanne that specializes in the development and promotion of injectable biomaterials aimed at preventing fractures in fragile bones. Its innovative technology focuses on minimal-invasive augmentation, allowing weak bones to strengthen themselves without disrupting natural bone mechanics or blood flow. The company's biomaterials are designed to stimulate the body's self-healing capabilities, addressing the needs of patients with chronic insufficiency fractures and optimizing bone health, particularly in spine surgery. Flowbone's mission is to enhance the quality of life and independence for the elderly, helping them avoid the severe consequences associated with fragility fractures.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

MimiX Biotherapeutics Sàrl is a Swiss company founded in 2016 that specializes in biofabrication technology focused on tissue manufacturing for therapeutic and diagnostic applications. Based in La Tène, the company aims to revolutionize regenerative and personalized medicine through its innovative point-of-care approach. By developing ultra-fast biomanufacturing technology, MimiX Biotherapeutics seeks to create patient-specific biological tissue equivalents, facilitating tailored treatments that meet individual medical needs.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.

Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.

OptiChroniX is a Swiss-based digital health solutions company focused on enhancing brain health through early intervention. The company specializes in developing digital therapeutics that integrate biomedical, behavioral, computing, and engineering research. These interventions are deployed on smartphones and utilize data from wearable devices to personalize and monitor patients' health progress. OptiChroniX aims to improve clinical outcomes, quality of life, and cost-effectiveness by providing tailored coaching to enhance health literacy, medication adherence, and address modifiable risk factors associated with cognitive decline in conditions like Alzheimer’s disease and related comorbidities.

Terapet SA is a Switzerland-based company founded in 2019 at CERN by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals. The company specializes in developing advanced proton therapy technology for cancer treatment, which allows for precise targeting of tumors while minimizing damage to surrounding healthy tissue. This innovative approach leverages the unique properties of protons, which stop at a predetermined depth within the patient, enabling the delivery of a concentrated dose to the tumor. Terapet's system also provides real-time, three-dimensional monitoring of the proton dose administered, enhancing treatment accuracy and safety. With a focus on making cutting-edge cancer therapy more accessible and cost-effective, Terapet is preparing for the market launch of its initial product.

Neurosoft Bioelectronics is a Swiss company specializing in the development of soft implantable electrodes designed for interfacing with the nervous system. The company focuses on creating advanced neural implants that can record and stimulate the brain, spinal cord, and peripheral nerves, addressing the limitations of traditional stiff devices that hinder patient outcomes. Its flagship product, the SOFT ECoG, is a subdural electrode that facilitates effective brain monitoring and stimulation while minimizing electrical resistance and MRI artifacts. This innovative technology aims to achieve long-term bio-integration with neural tissues, adapting to both static and dynamic mechanical properties, which enhances therapeutic capabilities for patients suffering from neurological disorders. Ultimately, Neurosoft Bioelectronics strives to improve clinical outcomes and expand the potential applications of neural interfaces in healthcare.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

Endotelix is a privately held Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating diagnostic products and therapies aimed at detecting circulating antibodies associated with the condition. By providing fast, sensitive, and reliable diagnostic tests, Endotelix aims to enhance healthcare outcomes for vulnerable populations, including pregnant women and adolescent children. The company is committed to reducing pregnancy-related complications and improving overall healthcare delivery through its advanced research and diagnostic tools.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

Swiss Medical Union SA is a healthcare technology company based in Yverdon-les-Bains, Switzerland, founded in 2019. The company specializes in the manufacture of Micro-Bioreactors, which are used to test the interaction, efficiency, and safety of new medical products using models of human organs and tissues. This innovative equipment enables the selection of appropriate therapies ex vivo tailored to individual patient needs. In addition to its bioreactor technology, Swiss Medical Union develops software that simulates the activity of multiple organs, facilitating real-time analysis of interactions between active products and specific human organs. This technology allows monitoring of the effects of injected products within the circulatory system. The company also offers clinical testing services to hospitals, healthcare institutions, government clients, and international clinical facilities, supporting medical professionals in making informed decisions, particularly in cancer treatment.

Galventa is a company dedicated to improving sleep and wakefulness through innovative technological solutions. They specialize in developing clinically tested galenic platform technologies designed to enhance sleep quality and mitigate symptoms of sleep inertia. Their primary product is a food supplement based on micro-pellets, engineered to create time-controlled release systems. This supplement aims to regulate the sleep-wake cycle and synchronize the circadian clock, helping individuals with sleep inertia align their sleep patterns with their daily routines.

MaxWell Biosystems AG is an electronics and biotechnology company headquartered in Zurich, Switzerland, established in 2016. The company specializes in advancing neuroscience research and enhancing preclinical drug discovery through its innovative instrumentation. Its flagship product, MaxOne, is a sophisticated electrophysiology platform that features a high-density microelectrode array with 26,400 electrodes, enabling the recording and stimulation of electrogenic cells in vitro. This platform is equipped with 1024 low-noise readout channels and 32 stimulation channels, facilitating the extraction of both single-cell and network parameters. By utilizing this technology, MaxWell Biosystems significantly reduces the time required for characterizing cell functions, enabling researchers to complete processes that previously took several months in just a few weeks.

Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Bloom Biorenewables Ltd is a Swiss company established in 2019, specializing in the development of innovative technologies that convert wood and agricultural waste into renewable materials as substitutes for petroleum-based products. The company focuses on producing bio-based materials for various sectors, including fragrances, plastics, and textiles, thereby offering sustainable alternatives to fossil fuels. By introducing a novel approach to the production of biorenewable products and fuels, Bloom Biorenewables aims to make a significant impact in promoting the use of sustainable resources and addressing climate change challenges.

KaleiBox is a company based in Zurich, Switzerland, specializing in the development of three-dimensional optical imaging devices specifically designed for small-animal imaging. It offers two main products: the standalone-mode KaleiBox and a hybrid-mode KaleiBox, both of which facilitate fluorescence tomography with an emphasis on compact hardware design and advanced software. The company's devices serve various applications, including research laboratories, biotechnological industries, agricultural diagnostics, and image-guided surgical procedures. Drawing inspiration from the kaleidoscope, KaleiBox focuses on versatility and portability, aiming to enhance the current workflow in 3D fluorescence imaging, particularly for preclinical studies.

4i Labs generates multiplexed images of biological samples for molecular view of tumours.

Microcaps AG is a company based in Zurich, Switzerland, founded in 2018, specializing in the development of advanced microencapsulation technology. The firm focuses on creating devices that facilitate the precise production of monodisperse microcapsules and microparticles through innovative microfluidics. Microcaps' solutions are designed to enhance drug delivery systems and probiotic encapsulation, while also providing tailored offerings for various applications, including pharmaceuticals and cosmetics. Their cutting-edge technology enables scalable, fully-automated production that allows for size control, precise dosing, and improved stability of the encapsulated materials. By utilizing a step emulsification device, Microcaps enhances production capacity and throughput rates without compromising quality, making it a pivotal player in the field of microencapsulation.

Endotelix is a privately held Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating diagnostic products and therapies aimed at detecting circulating antibodies associated with the condition. By providing fast, sensitive, and reliable diagnostic tests, Endotelix aims to enhance healthcare outcomes for vulnerable populations, including pregnant women and adolescent children. The company is committed to reducing pregnancy-related complications and improving overall healthcare delivery through its advanced research and diagnostic tools.

Alibion AG is a therapeutics development company founded in 2018 and located in Allschwil, Switzerland. The company aims to bridge the gap between academic drug discoveries and patient access by accelerating the early-stage development of novel therapeutics. Recognizing that many promising therapies developed in academic settings often fail to progress to preclinical and clinical testing due to a lack of development partners, Alibion focuses on identifying and advancing these innovative compounds. By pooling necessary resources and managing drug development through outsourced partners, Alibion seeks to streamline processes, reduce costs, and ensure compliance with quality standards. Ultimately, the company is dedicated to improving patient outcomes globally by facilitating the transition of new therapies from labs to late-stage development.

Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Mitoscreening platform (MSP) is used to screen metabolism-targeting anti-cancer drugs to discover.

Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of innovative healthcare devices. The company has created EmbryoSpin, a device that performs microscopic Nuclear Magnetic Resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold. This groundbreaking device is designed to operate at the scale of a single human embryo, providing a robust and user-friendly solution for researchers. EmbryoSpin facilitates non-invasive embryo viability screening for in-vitro fertilization and enhances biochemical research by allowing detailed chemical analysis of microscopic samples. Annaida Technologies' advancements aim to improve outcomes in reproductive health and deepen understanding in various areas of biochemical research.

Evictas is a biotechnology company.

Viventis Microscopy develops an innovative light sheet microscope system designed for long-term live imaging of light-sensitive samples, such as embryos and organoids. The company provides both the hardware and custom microscope control software, facilitating advanced imaging capabilities for researchers and organizations. By enabling detailed observation of delicate biological structures, Viventis Microscopy supports efforts in drug development and other scientific endeavors, helping to accelerate research and enhance the understanding of complex biological processes.

Endotelix is a privately held Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating diagnostic products and therapies aimed at detecting circulating antibodies associated with the condition. By providing fast, sensitive, and reliable diagnostic tests, Endotelix aims to enhance healthcare outcomes for vulnerable populations, including pregnant women and adolescent children. The company is committed to reducing pregnancy-related complications and improving overall healthcare delivery through its advanced research and diagnostic tools.

Prolongate is a protein drugs and biotech company.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

BIOMEM

Nagi Bioscience SA is a Swiss company based in Lausanne that specializes in developing and manufacturing an innovative automated testing device utilizing organism-on-chip technology. This device leverages the microscopic worm Caenorhabditis elegans for in vivo testing, enabling pharmaceutical, chemical, and cosmetic companies to assess the toxic and beneficial effects of various substances. By integrating fully automated in vitro handling, culture, and analysis, Nagi Bioscience's platform facilitates toxicity testing, drug discovery, and anthelmintic testing. This approach allows clients to evaluate comprehensive biological responses that can only be observed at the level of the whole organism, thereby transforming traditional testing methodologies.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.